Dr. Andre Barkhuizen, M.D.
Rheumatology (Rheumatology Physician)
- Medicare participating
At a glance
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 139
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Rheumatology Physician primary
OR license MD20458
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Medicare patients and services
- Medicare patients, 2024
- 139
- Services billed
- 40,497
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Injection, golimumab, 1 mg, for intravenous use | 16,935 | 18 |
| Injection, infliximab, excludes biosimilar, 10 mg | 4,420 | 14 |
| Established patient office or other outpatient visit, 30-39 minutes | 357 | 166 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 166 | 24 |
| Administration of chemotherapy into vein, each additional hour | 110 | 17 |
| Administration of chemotherapy into vein, 1 hour or less | 101 | 17 |
| Insertion of needle into vein for collection of blood sample | 84 | 51 |
| Established patient office or other outpatient visit, 20-29 minutes | 32 | 22 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Prednisone Other prescribers in Portland, OR | 292 |
| Methotrexate (methotrexate sodium) Other prescribers in Portland, OR | 261 |
| Hydroxychloroquine Sulfate Other prescribers in Portland, OR | 188 |
| Hydrocodone-Acetaminophen (hydrocodone/acetaminophen) Other prescribers in Portland, OR | 186 |
| Oxycodone Hcl Other prescribers in Portland, OR | 75 |
| Tramadol Hcl Other prescribers in Portland, OR | 73 |
| Folic Acid Other prescribers in Portland, OR | 68 |
| Azathioprine Other prescribers in Portland, OR | 58 |
| Sulfasalazine Other prescribers in Portland, OR | 46 |
| Oxycodone-Acetaminophen (oxycodone hcl/acetaminophen) Other prescribers in Portland, OR | 43 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Industry-funded research
Named as a principal investigator on 17 industry-funded studies in 2025, from 7 companies. The companies reported $1,476,290 in research payments for these studies, mostly to the institutions running them.
- A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of Age
ModernaTX, Inc. · Completed · NCT06602024 - A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight
Eli Lilly and Company · Completed · NCT05929066 - Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine
AbbVie Inc. · Active, not recruiting · NCT06417775 - A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee
Eli Lilly and Company · Completed · NCT05931367 - A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes
Eli Lilly and Company · Completed · NCT04255433 - A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Nave to Biologic Disease-modifying Anti-rheumatic Drugs
E.r. Squibb & Sons, L.l.c. - Efficacy and Safety of Tildrakizumab Compared to Placebo in Anti-TNF naive Subjects With Active Psoriatic Arthritis II (INSPIRE 2)
Sun Pharmaceutical Industries Inc. - M23-714 - Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine
AbbVie Inc. - Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight
Eli Lilly and Company · Completed · NCT06588296 - A phase 3 study to evaluate the safety tolerability and immunogenicity of a respiratory syncytial virus rsv prefusion f subunit vaccine in adults 60 years of age and older
Pfizer Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.